Document Detail


Gene therapy for ischemic heart disease.
MedLine Citation:
PMID:  21434842     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Coronary artery disease (CAD) is still the leading cause of death in industrialized nations. Even though revascularization strategies such as percutaneous coronary intervention (PCI) and coronary artery bypass graft surgery (CABG) as well as drug therapy have significantly reduced mortality, about 30% of patients will develop chronic heart failure over time. Ischemic heart disease and heart failure are characterized by an adverse remodeling of the heart, featuring cardiomyocyte hypertrophy, increased fibrosis and capillary rarification.
AREAS COVERED: Beside an assessment of current vector systems, this review focuses on potential target genes affecting angiogenesis/arteriogenesis and contractility. The potential of micro RNA (miRNA) modulation for the de-repression of survival and pro-angiogenic genes is discussed. Since gene therapy of the target region is preferable to avoid systemic contamination, application routes are discussed. Expert opinion: miRNAs are a promising new development for successful gene therapy, especially for acute myocardial infarction since their miRNA antagonists are easy to apply and appear to be selectively absorbed by the ischemic myocardial tissue. Rapid uptake and prolonged presence of known antimirs and antagomirs support this notion. For ischemic heart disease the most promising gene therapeutic approach seems to be the regional intravenous application of suitable AAV vectors and vascular growth factors, providing the full scope of angiogenesis, vessel maturation and collateral growth optionally combined with genes enhancing contractility.
Authors:
Rabea Hinkel; Teresa Trenkwalder; Christian Kupatt
Publication Detail:
Type:  Journal Article; Review     Date:  2011-03-25
Journal Detail:
Title:  Expert opinion on biological therapy     Volume:  11     ISSN:  1744-7682     ISO Abbreviation:  Expert Opin Biol Ther     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-06     Completed Date:  2011-09-01     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  101125414     Medline TA:  Expert Opin Biol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  723-37     Citation Subset:  IM    
Affiliation:
University Clinic Grosshadern, Internal medicine I, 81377 Munich, Germany. rabea.hinkel@med.uni-muenchen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Genetic Therapy*
Genetic Vectors
Humans
Myocardial Ischemia / therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
Next Document:  Decompressive craniectomy in diffuse traumatic brain injury.